KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Accured Expenses (2016 - 2025)

Inovio Pharmaceuticals' Change in Accured Expenses history spans 16 years, with the latest figure at -$350130.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 82.31% year-over-year to -$350130.0; the TTM value through Sep 2025 reached -$874216.0, down 380.2%, while the annual FY2024 figure was -$3.4 million, 92.68% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$350130.0 at Inovio Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $27.3 million in Q3 2022 and bottomed at -$40.7 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is -$182478.0 (2022), against an average of -$1.4 million.
  • The largest annual shift saw Change in Accured Expenses soared 105397.39% in 2021 before it crashed 274673.23% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $18.9 million in 2021, then tumbled by 244.88% to -$27.3 million in 2022, then surged by 117.02% to $4.7 million in 2023, then tumbled by 79.07% to $973719.0 in 2024, then tumbled by 135.96% to -$350130.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Change in Accured Expenses are -$350130.0 (Q3 2025), $2.7 million (Q2 2025), and -$4.2 million (Q1 2025).